HeartSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by HeartSciences Inc. (HSCS) on July 14, 2025, covering events occurring on July 9, 2025, and updates as of July 11, 2025. The company is an emerging growth company incorporated in Texas, focused on developing the MyoVista Device and MyoVista Insights platform.
Key Financial Metrics and Capital Activities
The filing does not provide standard financial metrics such as revenue, net income, operating cash flow, or debt levels for a specific reporting period. However, it details recent capital raising and equity issuance activities:
- Regulation A Offering: As of July 11, 2025, the company raised $1.7 million in gross proceeds from the sale of 487,701 Units (Series D Preferred Stock and Warrants).
- Debt Exchange: The company exchanged $855,000 of unsecured promissory notes for 233,229 shares of common stock.
- Outstanding Shares: Following the Reg A conversions and debt exchange, 1,555,049 shares of common stock were issued and outstanding as of July 11, 2025.
Material Changes and Corporate Actions
Significant corporate actions taken on July 9, 2025, include:
- Equity Plan Amendment: The Board approved an amendment to increase the maximum aggregate number of shares available under the 2023 Equity Incentive Plan to 1,000,000 shares. This requires shareholder approval at the next annual meeting.
- Executive Compensation Awards:
- RSUs: CEO Andrew Simpson received 68,750 RSUs; COO Mark Hilz received 56,250 RSUs. These vest immediately upon FDA clearance of the MyoVista Device or platform, or upon a Change of Control.
- Stock Options (Executives): CEO Simpson received 275,000 options; COO Hilz received 225,000 options; CFO Danielle Watson received 25,000 options. Exercise price is $4.37 per share. Vesting occurs over three years with acceleration upon FDA clearance.
- Stock Options (Directors): Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells each received 25,000 options at an exercise price of $4.37 per share, vesting quarterly starting October 9, 2025.
Outlook, Risks, and Contingencies
The filing highlights the company's reliance on regulatory milestones for compensation vesting and capital structure. Key points include:
- Regulatory Milestones: Vesting of significant equity awards is contingent upon FDA clearance of the MyoVista Device (including AI algorithm) or the MyoVista Insights platform.
- Capital Raising Status: The Regulation A offering, qualified on March 10, 2025, targets a maximum of $15,000,000. As of July 11, 2025, approximately 11.3% of the target ($1.7 million) has been raised.
- Dilution Risk: Recent issuances of common stock via the Reg A offering and debt exchange have increased the share count, which may impact future per-share metrics.
Investor Verification Checklist
- Verify the current status and timeline for FDA clearance of the MyoVista Device and Insights platform, as this triggers immediate vesting of executive RSUs and options.
- Confirm the remaining capacity and progress of the Regulation A offering to reach the $15 million target.
- Review the shareholder vote schedule for the approval of the 1,000,000 share increase to the Equity Incentive Plan.
- Assess the impact of the $855,000 debt exchange on the company's remaining unsecured debt obligations.
- Monitor the dilution effect of the 1,555,049 outstanding shares relative to future capital needs.